London
· Delayed Price · Currency is GBP · Price in USD Teva Pharmaceutical Industries Statistics
Total Valuation
Teva Pharmaceutical Industries has a market cap or net worth of GBP 16.18 billion. The enterprise value is 28.35 billion.
| Market Cap | 16.18B |
| Enterprise Value | 28.35B |
Important Dates
The last earnings date was Tuesday, January 28, 2025.
| Earnings Date | Jan 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.13B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.05, with an EV/FCF ratio of 47.39.
| EV / Earnings | -21.66 |
| EV / Sales | 2.13 |
| EV / EBITDA | 11.05 |
| EV / EBIT | 17.71 |
| EV / FCF | 47.39 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 3.36.
| Current Ratio | 0.98 |
| Quick Ratio | 0.50 |
| Debt / Equity | 3.36 |
| Debt / EBITDA | 5.67 |
| Debt / FCF | 24.14 |
| Interest Coverage | 2.03 |
Financial Efficiency
Return on equity (ROE) is -29.01% and return on invested capital (ROIC) is 4.79%.
| Return on Equity (ROE) | -29.01% |
| Return on Assets (ROA) | 3.00% |
| Return on Invested Capital (ROIC) | 4.79% |
| Return on Capital Employed (ROCE) | 7.50% |
| Revenue Per Employee | 357,158 |
| Profits Per Employee | -35,383 |
| Employee Count | 36,472 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.07% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +60.07% |
| 50-Day Moving Average | 19.80 |
| 200-Day Moving Average | 17.79 |
| Relative Strength Index (RSI) | 32.82 |
| Average Volume (20 Days) | 15,389 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries had revenue of GBP 13.21 billion and -1.31 billion in losses. Loss per share was -1.16.
| Revenue | 13.21B |
| Gross Profit | 6.44B |
| Operating Income | 1.59B |
| Pretax Income | -1.02B |
| Net Income | -1.31B |
| EBITDA | 2.43B |
| EBIT | 1.59B |
| Loss Per Share | -1.16 |
Balance Sheet
The company has 2.64 billion in cash and 14.44 billion in debt, giving a net cash position of -11.81 billion.
| Cash & Cash Equivalents | 2.64B |
| Total Debt | 14.44B |
| Net Cash | -11.81B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.30B |
| Book Value Per Share | 3.79 |
| Working Capital | -194.90M |
Cash Flow
In the last 12 months, operating cash flow was 996.07 million and capital expenditures -397.79 million, giving a free cash flow of 598.28 million.
| Operating Cash Flow | 996.07M |
| Capital Expenditures | -397.79M |
| Free Cash Flow | 598.28M |
| FCF Per Share | n/a |
Margins
Gross margin is 48.74%, with operating and profit margins of 12.02% and -9.91%.
| Gross Margin | 48.74% |
| Operating Margin | 12.02% |
| Pretax Margin | -7.76% |
| Profit Margin | -9.91% |
| EBITDA Margin | 18.42% |
| EBIT Margin | 12.02% |
| FCF Margin | 4.53% |
Dividends & Yields
Teva Pharmaceutical Industries does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | -8.09% |
| FCF Yield | 3.70% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |